All In Biotech

Drug Trial Radar · NCT06953271

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Jan 30, 2027

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Women and Infants Hospital of Rhode IslandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-procedural prophylaxis medications.

Conditions

  • Overactive Bladder (OAB)
  • Urinary Tract Infection (Diagnosis)

Interventions

  • Methenamine HippurateDrug

    Drug: Methenamine hippurate 1 gram by mouth twice daily for three days.

  • Typically prescribed oral antibiotic prophylaxisDrug

    Drug: typically prescribed oral antibiotic prophylaxis following intradetrusor BOTOX-A injections. This includes, but is not limited to, antibiotic medications such as nitrofurantoin, amoxicillin/clavulanic acid, and trimethoprim/sulfamethoxazole. Dosage will be determined per usual care. Duration of treatment will be standardized to three days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute Urinary Tract InfectionTime frame: Date of the BOTOX-A injection to 30 days after the procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Women & Infants Hospital

    Providence, Rhode Island · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.